Multiple Autoimmune Diseases after Autologous Stem-Cell Transplantation
To the Editor: Hematopoietic stemcell trans plantation can be an effective treatment in pa tients with refractory systemic sclerosis. 1 We report on a 19yearold woman with systemic sclerosis who underwent CD34+selected autolo gous hematopoietic stemcell transplantation in March 2001. Before the transplantation, the phys ical and laboratory findings showed no evidence of any other autoimmune diseases. After written consent was obtained from the patient, CD34+ hematopoietic stem cells were transplanted ac cording to a method used for systemic sclerosis. 1 The dermal sclerosis improved immediately after transplantation, but thrombocytopenia and Graves' disease developed. In June 2005, the patient was admitted to the , Graves' disease, systemic edema, and cerebral infarction) and changes in titers of each autoantibody. At the onset of edema, a serum sample from the patient contained anti-Sm, anti-Scl70, and anticardiolipin IgG antibodies (IgG-aCL), in addition to anti-DNA autoantibodies and lupus anticoagulant. The solid line indicates the modified Rodnan total skin thickness score (ranging from 0 to 51, with higher values indicating more thickness). Normal ranges for these levels are as follows: anti-Sm, 0 to 5.9 U per milliliter, anti-Scl70, 0 to 18.9 U per milliliter; and IgG-aCL, <1.3 U per milliliter. Panel B shows serum levels of interleukin-17, transforming growth factor β1 (TGF-β1), and interleukin-6. Normal ranges for these levels are as follows: TGF-β1, 30.95 to 38.65 ng per milliliter; interleukin-6, 0.54 to 1.10 ng per milliliter; and interleukin-17, not detected. Panel C shows changes in T cells, including the ratio of interferon-γ-producing CD4+ T cells (Th1) and interleukin-4-producing CD4+ T cells (Th2) and FOXP3 messenger RNA (mRNA) on peripheral-blood mononuclear cells. hospital because of fever and edema. Blood tests revealed proteinuria (11.4 g per day) and new autoantibodies in the serum (Fig. 1A) . On the sixth hospital day, paralysis developed on the left side as the result of a right cerebral infarction. Systemic lupus erythematosus with membranous type lupus nephritis (Fig. 2) and the antiphos pholipidantibody syndrome were diagnosed; the patient was treated with prednisolone, warfarin, and cyclosporine. She is currently in clinical re mission and is back at work. During the early phases of immune reconsti tution, residual lymphocytes undergo prolifera tion and expansion, a process controlled by regulatory T cells. 2,3 These cells, defined by the phenotype CD4+CD25+FOXP3+, are important in the prevention of autoimmunity. Interleukin 17-producing helper T (Th17) cells may play a role in the induction of autoimmunity. 4,5 In our patient, the level of serum interleukin17, re leased mainly by Th17 cells, was elevated at the onset of the systemic lupus (Fig. 1B) . Levels of FOXP3 messenger RNA, a marker of regulatory T cells, were reduced, suggesting a deficiency of such cells (Fig. 1C) . The findings in our patient suggest a role of both regulatory T cells and Th17 in the development of systemic lupus. 
